11 April 2024 - LYT-200 is being evaluated in locally advanced/metastatic solid tumours, including head and neck cancers, as well as in haematological malignancies, such as acute myeloid leukaemia and high-risk myelodysplastic syndrome.

PureTech Health today announced that the US FDA has granted fast track designation for LYT-200 in combination with anti-PD1 therapy for the treatment of recurrent/metastatic head and neck squamous cell carcinomas.

Read PureTech Health press release